Join Growin Stock Community!

友華4120.TW Overview

TW StockBiotech. & Medical
(No presentation for 4120)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

友華（4120）Overall Performance

友華（4120）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

友華（4120） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

友華（4120）Key Information

友華（4120）Profile

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. Orient EuroPharma Co., Ltd. was founded in 1982 and is based in Taipei, Taiwan.

友華（4120）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
17.44
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
48.56%
Net Margin
-10.22%
Revenue Growth (YoY)
1.16%
Profit Growth (YoY)
1.50%
3-Year Revenue Growth
-2.48%
3-Year Profit Growth
0.49%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
17.44
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
48.56%
Net Margin
-10.22%
Revenue Growth (YoY)
1.16%
Profit Growth (YoY)
1.50%
3-Year Revenue Growth
-2.48%
3-Year Profit Growth
0.49%
default symbol

4120

友華

43.95D

-0.68%

(-0.01)

  • When is 4120's latest earnings report released?

    The most recent financial report for 友華 (4120) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4120's short-term business performance and financial health. For the latest updates on 4120's earnings releases, visit this page regularly.

  • What is the operating profit of 4120?

    According to the latest financial report, 友華 (4120) reported an Operating Profit of -40.66M with an Operating Margin of -3.65% this period, representing a decline of 41.79% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4120's revenue growth?

    In the latest financial report, 友華 (4120) announced revenue of 1.12B, with a Year-Over-Year growth rate of 4.51%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4120 have?

    At the end of the period, 友華 (4120) held Total Cash and Cash Equivalents of 1.99B, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4120 go with three margins increasing?

    In the latest report, 友華 (4120) did not achieve the “three margins increasing” benchmark, with a gross margin of 49.61%%, operating margin of -3.65%%, and net margin of -9.65%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4120's profit trajectory and future growth potential.

  • Is 4120's EPS continuing to grow?

    According to the past four quarterly reports, 友華 (4120)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.49. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4120?

    友華 (4120)'s Free Cash Flow (FCF) for the period is -627.6M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 673.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.